Erythromycin derivatives

OBJECTS OF THE INVENTION
It is another object of the invention to provide novel compounds of formula I and their non-toxic, pharmaceutically acceptable acid addition salts and a process for their preparation.
It is another object of the invention to provide novel antibiotic compositions and a novel method of combatting bacterial infections in warm-blooded animals.
These and other objects and advantages of the invention will become obvious from the following detailed description.
THE INVENTION
The novel compounds of the invention are selected from the group consisting of all possible stereoisomeric forms and mixtures thereof of a compound of the formula ##STR2## wherein X and Y are hydrogen or together form ##STR3## R is --(CH.sub.2).sub.m -- ##STR4## m is an integer from 0 to 20, n is 0, 1, 2 or 3, A and B are individually selected from the group consisting of hydrogen, halogen, alkyl of 1 to 8 carbon atoms and aryl of 6 to 8 carbon atoms with the double bond geometry being E or Z or a mixture of E and Z or A and B form a third bond between the carbons to which they are attached, X.sub.A is selected from the group consisting of alkyl, alkenyl and alkynyl of 6 to 20 carbon atoms optionally interrupted with at least one heteroatom and optionally substituted with at least one halogen, cycloalkyl of 3 to 8 carbon atoms optionally substituted by a carbocyclic aryl, halogen, --CN, --OR.sub.3, COR.sub.4, --COOR.sub.5, --SR.sub.6, --SOR.sub.7, --SO.sub.2 R.sub.8, ##STR5## --OC(Ar).sub.3 and a carbocyclic aryl and heterocyclic aryl optionally substituted, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are individually selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms optionally interrupted by at least one heteroatom and optionally substituted by at least one halogen, carbocyclic and heterocyclic aryl and aralkyl of up to 14 carbon atoms optionally substituted with at least one member of the group consisting of free, salified, esterified or amidified carboxy, --OH, halogen, --NO.sub.2, --CN , alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, --SO-alkyl, --SO-alkenyl, --SO-alkynyl, --SO.sub.2 -- alkyl, --SO.sub.2 -alkenyl and --S.sub.2 -alkynyl of up to 12 carbon atoms, all optionally substituted with at least one halogen, carbocyclic and heterocyclic aryl O-aryl and --S-aryl of up to 14 carbon atoms, R'.sub.1 and R'.sub.2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 12 carbon atoms, R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen, alkyl of 1 to 20 carbon atoms, --COAlk and --COO-Alk, aryl, --CO-aryl, --COO-aryl, aralkyl, --CO-aralkyl and --COO-aralkyl of up to 14 carbon atoms, Alk is alkyl of 1 to 8 carbon atoms, or R.sub.1 and R.sub.2 together with the nitrogen to which they are attached form ring of 3 to 8 members optionally containing a second heteroatom and optionally substituted with the above aryl substituents, Ar is a carbocyclic aryl optionally substituted with at least one of the above aryl substituents, Z is hydrogen or aryl of an organic carboxylic acid of up to 18 carbon atoms and their non-toxic, pharmaceutically acid addition salts.
The compounds of formula I can exist in all their possible stereoisomeric forms, as well as their mixtures. The oxime in position 9, for example can be of E or Z geometry and includes the E oximes, the Z oximes as well as their E+Z mixtures.
Examples of the acids to form the non-toxic, pharmaceutically acceptable acid addition salts are acetic acid, propionic acid, trifluoroacetic acid, maleic acid, tartaric acid, methane-sulfonic acid, benzene-sulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid and stearic acid.
When X.sub.A is alkyl of 6 to 20 carbon atoms, it is preferably hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and hexadecyl, as well as their isomers.
In the definition of the substituents: halogen is preferably fluorine or chlorine or bromine, alkyl, alkenyl or alkynyl are preferably methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, decyl or dodecyl, vinyl, allyl, ethynyl, propynyl or propargyl. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
When alkyl is optionally interrupted by one or more heteroatoms, it is preferably one or more oxygen atoms. Carbocyclic aryl is preferably phenyl or naphthyl. By heterocyclic aryl is meant either a monocyclic heteroaryl of 5 or 6 ring members containing one or more heteroatoms, or a condensed polycyclic system, each ring containing 5 or 6 ring members and optionally one or more heteroatoms. Heterocyclic aryl may contain one or more heteroatoms preferably chosen from oxygen, sulfur and nitrogen.
Examples of monocyclic heteroaryl with 5 members are thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isoxazolyl. Examples of monocyclic heteroaryl with 6 members are pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl. Examples of condensed polycyclic heteroaryl are indolyl, benzofuryl, benzothienyl or quinolinyl, or the remainder of a purine base such as adenine.
The alkyl, alkenyl or alkynyl are preferably methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, decyl or dodecyl, vinyl, allyl, ethynyl, propynyl, propargyl, cyclobutyl, cyclopentyl or cyclohexyl and the carboxylic acid remainder is preferably acetyl, propionyl, butyryl, isobutyryl, n-valeryl, iso-valeryl, tert-valeryl or pivalyl.
Among the preferred compounds of the invention are the compounds of formula I in which X and Y are hydrogen, those in which Z is hydrogen, those in which R is ##STR6## m and n are 0, and X.sub.A is saturated or unsaturated alkyl of 8 to 16 carbon atoms optionally substituted by at least one halogen, or cycloalkyl of 3 to 6 carbon atoms, for example those in which R is undecyl, dodecyl, 3,7,11-trimethyl-2,6,10-dodecatrienyl or 3-cyclohexylpropyl, as well as their addition salts with acids.
Other preferred compounds of formula I are those wherein R is ##STR7## in which X.sub.A is phenyl optionally substituted by one of the radicals mentioned above as substituents of the aryl radicals, m, n, A and B are as defined above and preferably n is 0 or 1, or is an integer of 2 to 6 and those in which X.sub.A is phenyl optionally substituted by at least one member of the group consisting of halogen, methyl, trifluoromethyl, hydroxy, methoxy, phenyl or phenoxy optionally substituted by at least one halogen.
Also preferred are the compounds in which R is --(CH.sub.2).sub.3 Ar, --(CH.sub.2).sub.4 --Ar or --CH.sub.2 --CH.dbd.CH--Ar, Ar is optionally substituted phenyl, as well as their addition salts with acids and those wherein X.sub.A is
--O--C(C.sub.6 H.sub.5).sub.3
in which phenyl is optionally substituted by at least one of the substituents indicated above as well as their addition salts with acids.
Among the compounds of the invention, there can also be mentioned the compounds of formula I wherein X.sub.A is ##STR8## in which R.sub.1 and R.sub.2 are individually hydrogen or alkyl of up to 12 carbon atoms and particularly dodecylamino.
A more particular subject of the invention are the compounds of Examples 1, 2, 4, 5, 21, 25, 26, 33, 37, 38, 42, 48, 51, 54, 57, 64, 65 and 66.
The novel antibiotic components of the invention are comprised of an antibiotically effective amount of at least one compound of formula I and their non-toxic, pharmaceutically acceptable acid addition salts and an inert pharmaceutical carrier. The compositions may be in the form of tablets, dragees, capsules, granules, suppositories, ointments, creams, gels, and injectable solutions or suspension.
Examples of suitable inert pharmaceutical carriers are talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents and preservatives. The compositions can also be in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example apyrogenic sterile water.
The compositions have a very good antibiotic activity on gram positive bacteria such as staphylococci, streptococci and pneumococci and therefore can be used for the treatment of infections caused by sensitive germs and, particularly, staphylococcia such as staphylococcal septicemias, malignant staphylococcia of the face or skin, pyodermatitis, septic or suppurating wounds, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as acute primary or post-influenzal angina, bronchopneumonia, pulmonary suppuration, streptococcia such as acute anginas, otitis, sinusitis, scarlet fever, pneumococcia such as pneumonia, bronchitis; brucellosis, diptheria, gonococcal infection. The compositions are also active against infections caused by germs such as Haemophilus influenzae, Rickettsies, Mycoplasma pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma, Listeria, Campylobacter and Meningococcus.
The novel method of the invention for combatting bacterial infections in warm-blooded animals comprising administering to warmblooded animals an anti-bacterially effective amount of at least one compound of formula I and their non-toxic, pharmaceutically acceptable acid addition salts. The compounds may be administered rectally, orally or parenterally as well as topically to the skin or mucous membrane. The usual useful daily dose is 0.70 to 4 mg/kg depending on the condition treated, the compound used and the method of administration.
The process for the preparation of the compounds of formula I comprises reacting all possible stereoisomers and mixtures thereof of a compound of the formula ##STR9## wherein X, Y and Z have the above definitions with a compound of the formula
RCHO III
wherein R has the above definition to obtain the corresponding compound of formula I which is optionally reacted with an esterification agent to esterify the 2 '-hydroxyl or with an acid to form the acid addition salt.
Preferably, the compounds of formulae II and III are reacted in the presence of NaBH.sub.3 CN or in the presence of hydrogen and a suitable catalyst such as palladium on activated charcoal. The optional esterification of the 2'-hydroxyl may be effected with known procedures and the salification may be effected with the appropriate acid.
The compounds of formula II in all their stereoisomeric forms as well as their mixtures are described in European Patent Application 0487411. The compounds of formula II in which the 9-oxime is of E geometry can be obtained by chromatography starting with R+S diastereosiomer mixtures at the level of the 3-carbon of the piperidine, or can be obtained by using chiral (S) 3-hydroxy piperidine obtained by resolution using as active ingredient a chiral acid by the process described in European Patent Application 487411 (cf preparation of Example 27).
The compounds of formula III are known in a general manner and can be prepared by the reaction scheme
RCO.sub.2 H.fwdarw.RCH.sub.2 OH.fwdarw.RCHO
using standard processes.
In the following examples, there are described several preferred embodiments to illustrate the invention. However, it is to be understood that the invention is not intended to be limited to the specific embodiments.
The compounds prepared hereafter are prepared according to one of the following 3 general operating methods: In what follows, 3-de [(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(3-piperidinyl)oxime is called Product A.
Operating method 1
0.5 mM of product A, 0.5 mM of aldehyde were dissolved in 4 ml of methanol or 3 ml of methyl cyanide+1 ml of methanol and 0.1 ml of glacial acetic acid was added thereto. The mixture was stirred for 5 to 10 minutes and 0.55 mM of NaBH.sub.3 CN were added all at once. The mixture was stirred at ambient temperature for 15 to 60 minutes and then the solution was concentrated under reduced pressure. After taking the residue up in 10 ml of water and 30 ml of ethyl acetate, the pH was adjusted to about 8 with sodium hydroxide, followed by decanting, extracting, washing the aqueous phase with 10 ml of ethyl acetate, then washing the organic phases with a saturated solution of sodium chloride. After drying over magnesium sulfate, the product was purified by chromatographing on silica, eluting with mixtures of the following type: ethyl acetate-triethylamine; isopropyl ether-triethylamine-methanol; methylene chloride-methanol; methylene chloride-methanol-ammonium hydroxide; chloroform-methanol-ammonium hydroxide; ethyl acetate-methanol; ethyl acetate-methanol-triethylamine to obtain the desired product.
Operating method 2
0.4 mM of product A, 0.45 mM of aldehyde were dissolved in 10 ml of methanol and 30 .mu.l of glacial acetic acid and 50 mg of palladium on activated charcoal were added. The mixture was stirred under 1.5 atmospheres of hydrogen for 2 to 24 hours. The solution was filtered on clarcel, rinsed with 20 ml of methanol and the solution was concentrated. Purification was carried out by chromatographing on silica, eluting with one of the eluant systems in operating method 1 to obtain the desired product.
Operating method 3
0.2 mM of product A and 0.3 mM of aldehyde were dissolved in 0.6 ml of methyl cyanide and 0.5 ml of a solution of sodium acid phosphate and the mixture was stirred for 5 minutes. Then, 30 mg (0.48 mM) of NaBH.sub.3 CN were added and the pH was adjusted to approx. 4.5 by adding a hydrochloric acid solution dropwise. The reaction was completed in 5 to 60 minutes and 5 ml of water were added. The pH was adjusted to 8 with sodium hydroxide and extraction was carried out with 2.times.10 ml of chloroform. The organic phases were dried over magnesium sulfate and purification was carried out by chromatographing on silica using one of the eluant systems in operating method 1 to obtain the desired product.

EXAMPLE 1
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-phenylpropyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =804.sup.+ NMR CDCl.sub.3 ppm 2.25-2.75-2.98 (m) CH.sub.2 N; 2.26 (s) NCH.sub.3 ; 2.74 (s) 6-OCH.sub.3 ; 3.69 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) NOCH; 5.17 (dd) H.sub.13 ; 7.1 to 7.3 aromatics.
EXAMPLE 2
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl 3-oxo-erythromycin (R)(E) 9-O-(1-dodecyl-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =854.sup.+ NMR CDCl.sub.3 ppm 126 the (CH.sub.2 ).sub.n 's; 2.15 2.4-2.7-2.98 (m) CH.sub.2 N; 2.26 (s) NCH.sub.3 ; 2.74 (s) 6-OCH.sub.3 ; 3.68 (m) H.sub.8 ; 3.87 (q) H.sub.2 ; 4.04 (m) NOCH; 5.17 (dd) H.sub.13.
EXAMPLE 3
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E)9-O-(1-octyl-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =798.sup.+ NMR CDCl.sub.3 ppm 1.22 to 1.33 (CH.sub.2).sub.n and 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.74 (s) 6-OCH.sub.3 ; 2.2-2.7-2.98 the CH.sub.2 N's; 3.68 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) NOCH; 5.17 (dd) H.sub.13.
EXAMPLE 4
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxo]-6-O-methyl-3-oxo-erythromycin (R) (E)9-O-(1-(3-(3-methoxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =834.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.74 (s) 6-OCH.sub.3 ; 2.3 to 2.6 the CH.sub.2 N's; 3.68 (m) H.sub.8 ; 3.80 (s) .PHI.OCH.sub.3 ; 3.87 (q) H.sub.2 ; 4.04 (m) NOCH; 5.17 (dd) H.sub.13 ; 6.69-6.87-7.19 the aromatics.
EXAMPLE 5
3-de[(2,6-dideoxy-3-C-methyl-6-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(4-triphenylmethoxy)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =1000.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.1 to 2.4-2.97-2.72 the CH.sub.2 N's; 3.06 CH.sub.2 O; 3.66 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 5.17 (dd) H.sub.13 ; 7.17 to 7.30-7.44 (m) the aromatics.
EXAMPLE 6
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxo]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(4-hydroxybutyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =758.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.38 (sl) NCH.sub.2 2.74 (s) 6-OCH.sub.3 ; 3.56 (sl) CH.sub.2 OH; 3.70 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.08 (m) NOCH.
EXAMPLE 7
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxo]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(2-aminoethyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =729.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.4 (m)-2.76 (m) the CH.sub.2 N's; 3.68 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) NOCH; 5.17 (dd) H.sub.13.
EXAMPLE 8
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxo]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-(3-trifluoromethyl-phenyl)-oxy)benzyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =936.sup.+ NMR CDCl.sub.3 ppm 2.70 6-OMe; 3.86 (q,J=6 Hz) H.sub.2 ; 3.67 (E) H.sub.8 ; 2.27 N(CH.sub.3).sub.2 ; 3.40 (d,J=14 )-3.459 (d,J=14) N--CH.sub.2 --.PHI..
EXAMPLE 9
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxo]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(2-phenethyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =790.sup.+ NMR CDCl.sub.3 ppm 2.74 6-OMe; 3.86 H.sub.2 ; 3.70 (E) H.sub.8 ; 7.15 to 7.35 .PHI.-; 2.5 to 2.7-2.77-3.04 N--CH.sub.2 --CH.sub.2 --.PHI. and CH.sub.2 N.
EXAMPLE 10
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxo]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(4-(4-methoxyphenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =848.sup.+ NMR CDCl.sub.3 ppm 2.26 N(CH.sub.3) 2; 2.74 (s) 6-OMe; 3.68 H.sub.8 ; 3.79 .PHI.-OMe; 2.25 to 2.75-2.96 CH.sub.2 N and CH.sub.2 .PHI.; 3.87 H.sub.2.
EXAMPLE 11
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-(1-(benzyl)-1H-indol-4-yl)-propyl-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =933.sup.+ NMR CDCl.sub.3 ppm 2.26 N(CH.sub.3).sub.2 ; 2.74 6-OMe; 2.91 CH.sub.2 --.PHI.; 3.68 H.sub.8 ; 3.86 H.sub.2 ; 4.06 axial N--O--CH: 5.32 NCH.sub.2 .PHI.; 6.58-6.92-7.05 to 7.30 the aromatics.
EXAMPLE 12
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy)-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-imidazolylpropyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =794.sup.+ NMR CDCl.sub.3 ppm 2.26 N(Me).sub.2 ; 2.74 6-OMe; 3.18 H.sub.2' ; 3.68 H.sub.8 ; 3.89 H.sub.2 ; 4.00 CH.sub.2 --N--C.dbd.; 4.05 N--O--CH; 7.46-6.92-7.05 imidazole.
EXAMPLE 13
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(4-phenylbutyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =818.sup.+ NMR CDCl.sub.3 ppm 2.26 N(Me).sub.2 ; 2.62 CH.sub.2 --.PHI.; 2.73 6-OMe; 3.19 H.sub.2 '; 3.68 H.sub.8 ; 3.89 H.sub.2 ; 4.03 N--O--CH: 7.18-7.21 Aromatics.
EXAMPLE 14
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(((1,1'-biphenyl)-4-yl)-methyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =852.sup.+ NMR CDCl.sub.3 ppm 2.73 (s) 6-OMe; 3.69 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 3.47-3.63 (d) N--CH.sub.2 --.PHI.; 4.09 (m) axial NO--CH.
EXAMPLE 15
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(pentafluorobenzyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =866.sup.+ NMR CDCl.sub.3 ppm 6-OMe; 3.5 to 3.75 H.sub.8 ; 3.86 (q) H.sub.2 ; .about.3.72 N--CH.sub.2 --.PHI.; 4.03 (m) axial NO--CH.
EXAMPLE 16
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-((3-cyano-benzyl)-3-piperidinyl)-oxime was obtained using Operating Method 3 and its Mass spectrum: MH.sup.+ =800.sup.+ NMR CDCl.sub.3 ppm 2.68 (s) 6-OMe; 3.6 H.sub.8 ; 3.87 (q) H.sub.2 ; 3.43 (d) 3.60 N--CH.sub.2 --.PHI.; 4.07 (m) axial NO--CH.
EXAMPLE 17
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-((1H-imidazol-2-yl)-methyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =766.sup.+ NMR CDCl.sub.3 ppm 2.66 (s) 6-OMe; 3.5 to 3.7 H.sub.8 ; 3.87 (q) H.sub.2 ; 4.09 (m) NO--CH.
EXAMPLE 18
3-de[(2,6-dideoxy-3-C-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-((3-methyl-2-thienyl)-methyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =796.sup.+ NMR CDCl.sub.3 ppm 2.70 (s) 6-OMe; 3.5 to 3.75 H.sub.8 ; 3.86 (q) H.sub.2 ; 4.06 (m) axial NO--CH; 6.77 (d) 7.11 (d) H.sub.4 H.sub.5 thiophene.
EXAMPLE 19
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3,3-dimethylbutyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =770.sup.+ NMR CDCl.sub.3 ppm 2.74 (s) 6-OMe; 3.69 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) NO--CH.
EXAMPLE 20
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-(methylthio)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =774.sup.+ NMR CDCl.sub.3 ppm 2.74 (s) 6-OMe; 3.67 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) axial NO--CH.
EXAMPLE 21
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin trans (R) (E) 9-O-(1-(3-phenyl-2-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =802.sup.+ NMR CDCl.sub.3 ppm 2.74 (s) 6-OMe; 3.68 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.07 (m) axial NO--CH; 6.24 (dt, J=15.5 and 7) 6.49 (d, J=15.5 ethylenic .DELTA.E).
EXAMPLE 22
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(2-methoxy-benzyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =806.sup.+ NMR CDCl.sub.3 ppm 2.68 (s) 6-OMe; 3.5 to 3.75 H.sub.8 ; 3.86 (q) H.sub.2 ; 4.07 (m) axial NO--CH.
EXAMPLE 23
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-decyl-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =826.sup.+ NMR CDCl.sub.3 ppm 2.74 (s) 6-OMe; 3.68 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) axial NO--CH.
EXAMPLE 24
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(9-ethoxy 9-oxo-nonyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =870.sup.+ NMR CDCl.sub.3 ppm 2.74 (s) 6-OMe; 3.68 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.03 axial NO--CH.
EXAMPLE 25
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-(4-(trifluoromethyl)-phenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =872.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.67 CH.sub.2 .PHI.; 2.74 (s) 6-OCH.sub.3 ; 3.67 (m) H.sub.8 ; 3.87 (q) H.sub.2 ; 4.04 (m) NO--CH; 5.17 (dd) H.sub.13 ; 7.30-7.53 the aromatics.
EXAMPLE 26
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-(3,4-difluorophenyl)-propyl)-3-pyridinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =840.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.28 (s) NCH.sub.3 ; 2.58 CH.sub.2 .PHI.; 2.74 (s) 6-OCH.sub.3 ; 3.68 (m) H.sub.8 ; 3.87 (q) H.sub.2 ; 4.04 (m) NO--CH; 5.17 (dd) H.sub.13 ; 6.95-7.10 the aromatics.
EXAMPLE 27
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(2-phenoxyethyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =806.sup.+ NMR CDCl.sub.3 ppm 1.22 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.74 (s) 6-OCH.sub.3 ; 3.68 (m) H.sub.8 ; 3.86 (q) H.sub.2 ; 4.04 (m) NO--CH; 4.08 (t) CH.sub.2 O.PHI.; 5.17 (dd) H.sub.13 ; 6.85-7.25 the aromatics.
EXAMPLE 28
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy] -6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(2-((benzyl-amino)-ethyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =819.sup.+ NMR CDCl.sub.3 ppm 1.23 (S) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.73 (s) 6-OCH.sub.3 ; 3.66 (m) 3.80 (s) NCH.sub.2 .PHI.; 4.01 (m) NO--CH; 5.17 (dd) H.sub.13 ; 7.27-7.32 (m) the aromatics.
EXAMPLE 29
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(2-(methyl-benzyl-amino)-ethyl)-3-piperidinyl)oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =833.sup.+ NMR CDCl.sub.3 ppm 1.22 (s) 12CH.sub.3 ; 2.22 (s) NCH.sub.3 ; 2.26 (s) NCH.sub.3 desosamine; 2.76 (s) 6-OCH.sub.3 ; 3.51 (s) NCH.sub.2 .PHI.; 3.68 (m) H.sub.8 ; 3.87 (q) H.sub.2 ; 4.03 (m) NO--CH; 7.20 to 7.40 aromatics.
EXAMPLE 30
3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(3-(4-methoxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating method 1 and its Mass spectrum: MH.sup.+ =834.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12CH.sub.3 ; 2.26 (s) NCH.sub.3 ; 2.55 (m) CH.sub.2 .PHI.; 2.74 (s) 6-OCH.sub.3 ; 3.67 (m) H.sub.8 ; 3,79 (s) .PHI.OCH.sub.3 ; 3.86 (q) H.sub.2 ; 4.04 (m) NO--CH; 5.18 (dd) H.sub.13 ; 6.82-7.10 the aromatics,
EXAMPLE 31
3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-riboxhexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(2-((benzyl-((phenylmethoxy)-carbonyl)-amino)-ethyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =953.sup.+ NMR CDCl.sub.3 ppm 1.23 (s) 12Me; 2.26 (s) NCH.sub.3 ; 2.71 (s) 6-OCH.sub.3 ; 2.92-3.30-3.37 (m) NCH.sub.2 ; 3,68 (m) H.sub.8 ; 3.87 (q) H.sub.2 ; 3.98 (m) NOCH; 4.55 NCH.sub.2 --.PHI.; 7.2 to 7,40 the aromatics.
EXAMPLE 32
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-((2-benzofuranyl)-methyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =816.sup.+ NMR CDCl.sub.3 ppm 1.22: 12Me; 1.35: 6Me; 2.27: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.74: 6-OMe; 3.19: H.sub.2 '; 3,65: H.sub.8 ; 3.87: H.sub.2 ; 4.11: NO--CH; 6.56: benzofuran H.sub.3.
EXAMPLE 33
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin-(E) (Z) 9-O-(1-(4-(4-methylphenyl)butyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =832.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.37: 6Me; 2.26: N-(Me).sub.2 ; 2.57:H.sub.10 and CH.sub.2 .PHI.; 2.73: 6-OMe; 3.19: H.sub.2 '; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.03: NO--CH; 7.07: - - - .
EXAMPLE 34
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosy)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1-hexadecyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: MH.sup.+ =910.sup.+ NMR CDCl.sub.3 ppm 1.7-1.33: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.74: 6-OMe; 3.19: H.sub.2 '; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.04: NO--CH.
EXAMPLE 35
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(2-(1-oxononylamino)-ethyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its NMR CDCl.sub.3 ppm 1.32 (s): 6Me; 2.17 (t): CH.sub.2 --CO; 2.26 (s): N(Me).sub.2 ; 3.32 (m): CH.sub.2 NCO; 3.67 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.02 (m): NO--CH; 5.17 (dd): H.sub.13.
EXAMPLE 36
3-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin trans (E) (R) 9-O-(1-((2-phenyl-l-cyclopropyl)-methyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =816.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.35 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 3.67: 3.86 (q): H.sub.2 ; 4.05: NO--CH; 5.17 (dd): H.sub.13 ; 7.04-7.23: aromatics.
EXAMPLE 37
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-cyclohexylpropyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =810.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.37: 6Me; 2.28: N-(Me).sub.2 ; 2.57: H.sub.10 ; 2.73: 6-OMe; 3.20: H.sub.2 '; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.13: N--OCH.
EXAMPLE 38
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-hydroxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its NMR CDCl.sub.3 ppm 1.23: 12Me; 1.34: 6Me; 2.28: N-(Me).sub.2 ; 2.75: H.sub.10 ; CH.sub.2 .PHI.: 2.25 to 2.65; 2.66: 6-OMe; 3.19: H.sub.2 '; 3.65: H.sub.8 ; 3.88: H.sub.2 ; 4.07: NO--CH; 6.75-6.79: --.PHI.-O; 3.33-4.37: OH.
EXAMPLE 39
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(((phenylmethoxy)-carbonyl)-benzyl)-amino)-propyl)3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =967.9.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.37 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.72 (s): 6-OMe; 3.66 (m) : H.sub.8 ; 3.85 (q) : H.sub.2 ; 4.5: NCH.sub.2 Ar; 5.16: OCH.sub.2 Ar; 7.14 to 7.4: aromatics.
EXAMPLE 40
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3,3-diphenyl-2-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and it Mass spectrum: MH.sup.+ =877.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.36 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.70 (s): 6-OCH.sub.3 ; 3.66 (m): H.sub.8 ; 3.85 (q): H.sub.2 ; 4.04 (m): NO--CH; 6.17 (t)=CH; 7.10 to 7.4: aromatics.
EXAMPLE 41
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-chlorophenyl)-2 (E)-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =836.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.74 (s): 6-OMe; 3.68 (m): H.sub.8 ; 4.06 (m): NO--CH; 5.14 (dd): H.sub.13 ; 6.2 (dt) and 6.43 (d): ethylenics; 7.2-7.3: aromatics.
EXAMPLE 42
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3 -oxo-erythromycin (E) (R) 9-O-(1-undecyl-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =840.sup.+ NMR CDCl.sub.3 ppm 1.26 (m): CH.sub.2 n and 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.74 (s): 6-OMe; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.03 (m): NO--CH; 5.17 (dd): H.sub.13.
EXAMPLE 43
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1-3-benzyl-amino)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method and its NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.37 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.73 (s): 6-OMe; 3.67 (m): H.sub.8 ; 3.79 (AB): NCH.sub.2 Ar; 3.86 (q): H.sub.2 ; 3.99 (m): NO--CH; 7.24-7.32: aromatics.
EXAMPLE 44
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(8-phenyloctyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: MH.sup.+ =874.sup.+ NMR CDCl.sub.3 ppm 1.25: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.60: CH.sub.2 .PHI.; 2.74: 6-OMe; 3.18: H.sub.2 '; 3.68: H.sub.8 ; 3.85: H.sub.2 ; 4.03: N--OCH; 7.16-7.26: aromatics.
EXAMPLE 45
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1(3-(4-nitrophenyl)-2(E)-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 3 and its Mass spectrum: MH.sup.+ =847.sup.+ NMR CDCl.sub.3 ppm 1.22: 12Me; 1.37: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.73: 6-OMe; 3.05 to 3.20: H.sub.2 ', H.sub.4 ; 3.67: H.sub.8 ; 3.86: H.sub.2 ; 4.06: N--OCH; 7.5-8.17: --.PHI.-NO.sub.2.
EXAMPLE 46
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1(3-(methyloctylamino)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method and its Mass spectrum: MH.sup.+ =869.sup.+ NMR CDCl.sub.3 ppm 1.27 (s): 12Me; 1.38 (s): 6Me; 2.22 (s): N-Me; 2.26 (s): N-(Me).sub.2 ; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.03 (m): NO--CH; 5.17 (dd): H.sub.13.
EXAMPLE 47
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(3-((benzyl)-(4-phenyl-1-oxobutyl)-amino)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method and its Mass spectrum: MH.sup.+ =979.sup.+ NMR CDCl.sub.3 ppm
2.26 (s) : N-(Me).sub.2 ; 3.68 (m): H.sub.8 ; 3.98 (m): NO--CH; 4.48-4.6 (AB): NCH.sub.2 Ar; 5.16 (dd): H.sub.13 ; 7.05-7.4: the aromatics.
EXAMPLE 48
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(3-(1,1-biphenyl-4-yl)-2(E)-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =878.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.38 (s): 6Me; 2.25 (s): N-(Me).sub.2 ; 2.76 (s): 6-OMe; 3.69 (m) : H.sub.8 ; 3.86 (q) : H.sub.2 ; 5.16 (dd) H.sub.13 ; 6.29-6.53: ethylenics; 7.3-7.6: aromatics.
EXAMPLE 49
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(3-(methyl-benzyl)-amino)-propel)-3-piperidinyl)-oxime was obtained using Operating Method and its Mass spectrum: MH.sup.+ =847.sup.+ NMR CDCl.sub.3 ppm 1.25 (s): 12Me; 1.38 (s): 6Me; 2.18 (s) NMe; 2.25 (s): N-(Me).sub.2 ; 2.74 (s): 6-OMe; 3.47 (s): CH.sub.2 Ar; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 5.17: H.sub.13 ; 7.24-7.3: aromatics.
EXAMPLE 50
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosy)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-phenyl-1H-imidazol-1-yl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =870.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.38 (s): 6Me; 2.25 (s): N-(Me).sub.2 ; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.05 (m): NO--CH; 5.14 (dd): H.sub.13 ; 7.2-7.49: H imidazole; 7.22-7.36-7.76: the aromatics.
EXAMPLE 51
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-phenoxyphenyl)-2(E)-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =895.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.38 (s): 6Me; 2.27 (s): N-(Me).sub.2 ; 2.74 (s): 6-OMe; 3.69 (m) : H.sub.8 ; 3.86 (q): H.sub.2 ; 4.02 (m): NO--CH; 5.15 (dd): H.sub.13 ; 6.15 and 6.46 (J=16Hz): .dbd.CH; 6.9 to 7.4: aromatics.
EXAMPLE 52
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1(3-(4-butoxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =876.7.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.37: 6Me; 2.26: N-(Me).sub.2 ; 2.30-2.60: H.sub.10 ; 2.74: 6-OMe; 3.70: H.sub.2 '; 3.68: H.sub.8 ; 3.87: H.sub.2 ; 4.05: NO--CH; 3.95: --.PHI.-O--CH.sub.2 ; 6.85-7.08: -.PHI.-.
EXAMPLE 53
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(3-((((1,1 '-biphenyl-4-yl)-methyl)-amino)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method and its Mass spectrum: Mh.sup.+ =909.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 2.74 (s): 6-OMe; 3.45 (m): H.sub.8 ; 3.83 (s): CH.sub.2 Ar; 3.86: H.sub.2 ; 4.02 (m): NO--CH; 5.17 (dd): H.sub.13 ; 7.3-7.6: aromatics.
EXAMPLE 54
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(3-(dodecylamino)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method and its Mass spectrum: Mh.sup.+ =911.sup.+ NMR CDCl.sub.3 ppm 0.96-1.14: CH.sub.3 --(CH).sub.n ; 1.37 (s): 6Me; 2.3 (s): N-(Me).sub.2 ; 2.76 (s): 6-OMe; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 5.17 (dd): H.sub.13.
EXAMPLE 55
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(4-(2,4,6-trimethylphenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =860.sup.+ NMR CDCl.sub.3 ppm 1.22: 12Me; 1.37: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 3.18: H.sub.2 '; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.04: N--OCH; 7.4 to 7.7: -.PHI.-.
EXAMPLE 56
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(5-phenylpentyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.58: H.sub.10 ; 2.61: CH.sub.2 .PHI.; 2.74: 6-OMe; 3.18: H.sub.2 '; 3.67: H.sub.8 ; 3.85: H.sub.2 ; 4.04: N--OCH; 7.15 to 7.35: aromatics.
EXAMPLE 57
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl 3-oxo-erythromycin (E) (R) 9-O-(1-(3,7,11-trimethyl 2(E), 6(E), 10-dodecatrienyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =890.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.30 (s): 6Me; 1.6-1.62: vinyl CH.sub.3 's; 2.26 (s): N(Me).sub.2 ; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.05 (m): NO--CH; 5.05-5.25: vinyl H's.
EXAMPLE 58
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1(3-(3,4,5-trimethoxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =894.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.39: H.sub.10 ; 2.74: 6-OMe; 3.18: H.sub.2 '; 3.68: H.sub.8 ; 3.8: H.sub.2 ; 4.05: NO--CH; 6.41: aromatics.
EXAMPLE 59
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(5-((2-methoxyethoxy)-methoxy)-pentyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its NMR CDCl.sub.3 ppm 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.76 (s): 6-OMe; 3.52-3.71: OCH.sub.2 CH.sub.2 O; 3.82 (q): H.sub.2 ; 4.09: NO--CH; 4.72: OCH.sub.2 O: 5.17 (dd): H.sub.13.
EXAMPLE 60
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1(6-phenylhexyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =846.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 2.60: CH.sub.2 .PHI.; 2.74: 6-OMe; 3.19: H.sub.2 '; 3.69: H.sub.8 ; 3.87: Hz; 4.04: N--OCH; 7.10 to 7.30: the aromatics.
EXAMPLE 61
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(6-((4,6-dimethyl-2-pyrimidinyl)-thio)-hexyl)-3-piperidinyl)oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =908.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.39 (s): aromatic CH.sub.3 's; 2.7 (s): 6-OMe; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.04: NO--CH; 5.17 (dd): H.sub.13 ; 6.67: the aromatics.
EXAMPLE 62
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E)(R) 9-O-(1-(5-((4,4,5,5,5-pentafluoropentyl)-sulfonyl)-pentyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its NMR CDCl .sub.3 ppm 1.23 (S): 12Me; 1.38 (s): 6Me; 2.26 (m): N-(Me).sub.2 ; 2.76 (s): 6-OMe; 2.97-3.10: CH.sub.2 SO.sub.2 ; 3.67 (m): H.sub.8 ; 3.87 (q): H.sub.2 ; 4.02: NO--CH; 5.16 (dd): H.sub.13.
EXAMPLE 63
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-y-L-ribohexopyraosyl)-oxy] -6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1tetradecyl 3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =882.8.sup.+ NMR CDCl.sub.3 ppm 1.25: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.74: 6-OMe; 3.19: H.sub.2 '; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.04: NO--CH.
EXAMPLE 64
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromyc in (R) (E) 9 -O-(1-(4-(1,1'-biphenyl 4-yl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: Mh.sup.+ =894.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.39 (s): 6Me; 2.66 (t): CH.sub.2 Ar; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.05 (m): NO--CH; 5.17: H.sub.13 ; 7.25-7.59: aromatics.
EXAMPLE 65
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1(3-(4-phenoxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method and its Mass spectrum: Mh.sup.+ =896.sup.+ NMR CDCl.sub.3 ppm 1.22 (s): 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.6: CH.sub.2 Ar; 2.76 (s): 6-OMe; 3.86 (q): H.sub.2 ; 4. 05 (m): NO--CH; 5.17 (dd): H.sub.13 ; 6.85-7.9: aromatics.
EXAMPLE 66
3-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(4-(3-(3,5-dichlorophenoxy)-phenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =978.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.76 (s): 6-OMe; 3.67 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.03 (m): NO--CH; 5.18 (dd): H.sub.13 ; 6.85 (d)-7.05 (t)-6.82-7.29-7.03: aromatics.
EXAMPLE 67
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(6-((4-methylphenyl)-thio)-hexyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =892.sup.+ NMR CDCl.sub.3 ppm 1.22: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.31: CH.sub.3 --.PHI.; 2.56: H.sub.10 ; 2.74: 60Me; 2.87: S--CH.sub.2 ; 3.18: H.sub.2 '; 3.69: H.sub.8 ; 3.86: H.sub.2 ; 4.03: N--OCH.sub.2 ; 7.09 and 7.24: --.PHI.-S.
EXAMPLE 68
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1-(4-(4-butylphenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =874.6.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.58:H.sub.10 and CH.sub.2 .PHI.; 2.74: 6-Ome; 3.19: H.sub.2 '; 3.68: H.sub.8 ; 3.87: H.sub.2 ; 4.03: NO--CH; 7.08: -.PHI.-.
EXAMPLE 69
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (R) (E) 9-O-(1-(6-(4-chlorophenoxy)-hexyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =896.sup.+ NMR CDCl.sub.3 ppm 1.24: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.74: 6-OMe; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.04: axial .dbd.N--O--CH; 6.82: --.PHI.-Cl.
EXAMPLE 70
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1-(3-((4-methylphenyl)-thio)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =850.sup.+ NMR CDCl.sub.3 ppm 1.29 (s): 12Me; 1.37 (s): 6Me; 2.28 (s): N-(Me).sub.2 ; 2.32 (s): CH.sub.3 Ar; 2.99: CH.sub.2 --S; 3.67 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 5.17 (dd): H.sub.13 ; 7.09-7.25: aromatics.
EXAMPLE 71
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(4-(4-(1H-pyrrol-1-yl)-phenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: Mh.sup.+ =883.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.39 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.64: CH.sub.2 Ar; 2.76 (s): 6-OMe; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 4.04 (m): NO--CH; 5.18 (dd): H.sub.13 ; 6.33-7.07: pyrrole; 7.22-7.31: phenyl.
EXAMPLE 72
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1-(4-(5-butyl-2-pyridinyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: Mh.sup.+ =875.sup.+ NMR CDCl.sub.3 ppm 1.23 (s): 12Me; 1.38 (s): 6Me; 2.26 (s): N-(Me).sub.2 ; 2.57 (t) and 2.76 (t): benzyl CH.sub.2 ; 3.68 (m): H.sub.8 ; 3.86 (q): H.sub.2 ; 5.17 (dd): H.sub.13 ; 7.06-7.4-8.33: pyridine.
EXAMPLE 73
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(phenylmethoxy)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =832.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.56: H.sub.10 ; 2.73: 6-OMe; 3.18: H.sub.2 '; 3.50: OCH; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.03: axial N--O--CH; 4.5: O--CH.sub.2 .PHI.; 7.25 to 7.40: aromatics
EXAMPLE 74
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy] -6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-phenylcyclohexyl)-propel)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =886.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.26: N-(Me).sub.2 ; 2.57: H.sub.10 ; 3.18: H.sub.2 '; 3.68: H.sub.8 ; 3.86: H.sub.2 ; 4.05: axial N--O--CH; 7.14 to 7.30: aromatics.
EXAMPLE 75
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(4-(4-(4-pyridinyl)-phenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: Mh.sup.+ =895.sup.+ NMR CDCl.sub.3 ppm 1.23: 12Me; 1.38: 6Me; 2.27: N-(Me).sub.2 ; 2.58: H.sub.10 ; 2.69: CH.sub.2 .PHI.; 2.75: 6-OMe; 3.20: H.sub.2 '; 3.67: H.sub.8 ; 3.87: H.sub.2 ; 4.06: NOCH; 7.30-7.57: phenyl; 7.51-8.64: pyridine.
EXAMPLE 76
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9 -O-(1-(3-(4-methylphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 2 and its Mass spectrum: Mh.sup.+ =158, 818.sup.+ NMR CDCl.sub.3 ppm 2.31: CH.sub.3 .PHI.; 2.57: CH.sub.2 .PHI.; 3.67: H.sub.8 ; 4.04: NO--CH<; 7.08: phenyl.
EXAMPLE 77
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(3-hydroxyphenyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =158, 820.sup.+ NMR CDCl.sub.3 ppm 2.3 to 2.7: CH.sub.2 .PHI.; 3.65: H.sub.8 ; 4.06: NO--CH<; 6.67 (3H)-7.11 (1H): phenyl.
EXAMPLE 78
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(4-(4-hydroxyphenyl)-butyl)-3-piperidinyl)-oxime was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =834, 840.sup.+ NMR CDCl.sub.3 ppm 3.63: H.sub.8 ; 4.00: NO--CH<; 6.80-7.00: phenyl.
EXAMPLE 79
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-hydroxyphenyl)-propyl)-3-piperidinyl)-oxime 11,12-cyclic carbonate was obtained using Operating Method 1 and its Mass spectrum: Mh.sup.+ =846.sup.+ NMR CDCl.sub.3 ppm 1.38 (s)-1.55 (s): 6Me; 2.26 (s): N(Me).sub.2 ; 2.62 (s) 6-OMe; 3.67 (m): H.sub.8 (isomer E); 3.83 (q) : H.sub.2 4.09: NO--CH<; 5.05 (dd): H.sub.13 ; 6.76-7.05: hydroxyphenyl.
EXAMPLE 80
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1(3-(4-quinolinyl)-2(E)-propenyl)-3-piperidinyl)-oxime was obtained using Operating Method 1
EXAMPLE 81
3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribohexopyranosyl)-oxy]-6-O-methyl-3-oxo-erythromycin (E) (R) 9-O-(1-(3-(4-quinolinyl)-propyl)-3-piperidinyl)-oxime was obtained using Operating Method 1
EXAMPLE 82: of pharmaceutical composition
tablets were prepared corresponding to the following formula:
______________________________________Product of example 1 150 mgSufficient excipient for 1 g______________________________________
(detail of excipient: starch, talc, magnesium stearate).
EXAMPLE 83: of pharmaceutical composition
tablets were prepared corresponding to the following formula:
______________________________________Product of example 2 150 mgSufficient excipient for 1 g______________________________________
(detail of excipient: starch, talc, magnesium stearate).
EXAMPLE 84: of pharmaceutical composition
tablets were prepared corresponding to the following formula:
______________________________________Product of example 4 150 mgSufficient excipient for 1 g______________________________________
(detail of excipient: starch, talc, magnesium stearate).
PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION
A) Activity in vitro
Method of dilutions in liquid medium.
A series of tubes were prepared in which the same amount of sterile nutritive medium was distributed and increasing quantities of the product to be studied are distributed in each tube. Then, each tube was cultured with a bacterial strain and after incubation for twenty-four hours in an oven at 37.degree. C., the growth inhibition was assessed by transillumination which allowed the minimal inhibitory concentrations (M.I.C.) to be determined, expressed in micrograms/ml. The following results were obtained (readings after 24 hours).
______________________________________Product of Example 1Staphylococcus aureus 011UC4 0.3Staphylococcus aureus 011HT17 0.3Staphylococcus aureus 011G025I 1.2Staphylococcus epidermidis 012GO11C 0.3Streptococcus pyogenes group A 02A1UC1 0.08Streptococcus agalactiae group B 02B1HT1 .ltoreq.0.02Streptococcus sp group C 02C0CB3 0.08Streptococcus faecalis group D 02D2UC1 0.08Streptococcus faecium group D 02D3HT1 0.08Streptococcus sp group G 02G0Gr5 0.04Streptococcus mitis 02MitCB1 .ltoreq.0.02Streptococcus agalactiae group B 02B1SJ1 0.3Streptococcus sp group C 02C0CB1 0.15Streptococcus faecalis group D 02D2Gr8 1.2Streptococcus pneumoniae 032UC1 0.08Streptococcus pneumoniae 030SJ1 1.2Streptococcus pneumoniae 030SJ5 0.3Haemophilus influenzae 351HT3 5Haemophilus influenzae 351CB12 0.6Haemophilus influenzae 351CA1 2.5Product of Example 2Staphylococcus aureus 011UC4 1.2Staphylococcus aureus 011HT17 1.2Staphylococcus aureus 011B18C 5 Staphylococcus aureus 011GR12C 5Staphylococcus aureus 011G025I 2.5Staphylococcus epidermidis 012GO11C 1.2Staphylococcus aureus 011CB20 2.5Staphylococcus epidermidis 012GO40 2.5Streptococcus pyogenes group A 02A1UC1 0.3Streptococcus agalactiae group B 02B1HT1 1.2Streptococcus sp group C 02C0CB3 1.2Streptococcus faecalis group D 02D2UC1 0.3Streptococcus faecium group D 02D3HT1 0.3Streptococcus sp group G 02G0GR5 1.2Streptococcus mitis 02MitCB1 1.2Streptococcus pyogenes group A 02A1SJ1 1.2Streptococcus agalactiae group B 02B1SJ1 1.2Streptococcus sp group C 02C0CB1 0.6Streptococcus faecalis group D 02D2Gr8 2.5Streptococcus faecalis group D 02D2DU15 2.5Streptococcus sp group G 02G0GR4 1.2Streptococcus sanguis 02sgGR10 2.5Streptococcus mitis 02MitGR16 1.2Streptococcus pneumoniae 032UC1 1.2Streptococcus pneumoniae 030SJ1 1.2Streptococcus pneumoniae 030SJ5 2.5Haemophilus influenzae 351CB12 5Product of Example 4Staphylococcus aureus 011UC4 0.3Staphylococcus aureus 011UC4 + serum 0.3Staphylococcus epidermidis 012GO11i 1.2Streptococcus pyogenes group A 02A1UC1 0.08Streptococcus agalactiae group B 02B1HT1 .ltoreq.0.02Streptococcus faecalis 02D2UC1 0.08Streptococcus faecium group D 02D3HT1 0.08Streptococcus groups G 02G0Gr5 0.08Streptococcus mitis 02MitCB1 .ltoreq.0.02Streptococcus agalactiae 02B1SJ1c 0.3Streptococcus sanguis 02SgGR10i 0.08Streptococcus mitis 02MitGR16i 0.08Streptococcus pneumoniae 032UC1 0.3Streptococcus pneumoniae 030GR20 0.6Streptococcus pneumoniae 030SJ5i 0.15Streptococcus pneumoniae 030R01 0.3Streptococcus pneumoniae 030SJ1c 2.5Product of Example 5Staphylococcus aureus 011UC4 2.5Staphylococcus aureus 011G025i 5Staphylococcus aureus 011CB20c 5Staphylococcus epidermidis 012GO40c 5Streptococcus pyogenes group A 02A1UC1 0.3Streptococcus agalactiae group B 02B1HT1 0.08Streptococcus faecalis 02D2UC1 0.3Streptococcus faecium group D 02D3HT1 0.3Streptococcus group G 02G0Gr5 0.6Streptococcus mitis 02MitCB1 0.15Streptococcus pyogenes 02A1SJ1c 2.5Streptococcus agalactiae 02B1SJ1c 2.5Streptococcus faecalis group D 02D2DU15c 2.5Streptococcus sanguis 02SgGR10i 0.3Streptococcus mitis 02MitGR16i 0.6Streptococcus pneumoniae 032UC1 0.3Streptococcus pneumoniae 030GR20 0.3Streptococcus pneumoniae 030SJ5i 1.2Streptococcus pneumoniae 030cr18 2.5Streptococcus pneumoniae 030PW23 2.5Streptococcus pneumoniae 030R01 1.2Product of Example 21Staphylococcus aureus 011UC4 0.3Staphylococcus aureus 011UC4 + serum 0.15Staphylococcus aureus 011G025i 1.2Staphylococcus epidermidis 012GO11i 0.3Streptococcus pyogenes group A 02A1UC1 0.15Streptococcus agalactiae group B 02B1HT1 0.04Streptococcus faecalis 02D2UC1 0.15Streptococcus faecium group D 02D3HT1 0.15Streptococcus group G 02G0Gr5 0.15Streptococcus agalactiae 02B1SJ1c 0.6Streptococcus sanguis 02SgGR10i 0.8Streptococcus mitis 02MitGR16i 0.15Streptococcus pneumoniae 032UC1 0.04Streptococcus pneumoniae 030GR20 0.08Streptococcus pneumoniae 030SJ5i 0.3Streptococcus pneumoniae 030cr18 0.6Streptococcus pneumoniae 030PW23 2.5Streptococcus pneumoniae 030R01 0.3Haemophilus influenzae 351HT3 5Haemophilus influenzae 351CB12 0.6Haemophilus influenzae 351CA1 2.5Product of Example 26Staphylococcus aureus 011UC4 0.3Staphylococcus aureus 011UC4 + serum 0.6Staphylococcus aureus 011G025i 2.5Staphylococcus epidermidis 012GO11i 0.6Streptococcus pyogenes group A 02A1UC1 0.08Streptococcus agalactiae group B 02B1HT1 .ltoreq.0.02Streptococcus faecalis 02D2UC1 0.08Streptococcus faecium group D 02D3HT1 0.08Streptococcus group G 02G0Gr5 0.08Streptococcus mitis 02MitCB1 0.04Streptococcus agalactiae 02B1SJ1c 0.6Streptococcus sanguis 02SgGR10i 0.3Streptococcus pneumoniae 032UC1 0.3Streptococcus pneumoniae 030GR20 0.04Streptococcus pneumoniae 030SJ5i 0.6Haemophilus influenzae 351CB12 5______________________________________
Various modifications of the products and methods of the invention may be made without departing from the spirit or scope thereof and it is to be understood that the invention is to be limited only as defined in the appended claims.

Number	Date	Country
2534588	Apr 1984	FRX
0284203	Sep 1988	FRX
0487411	May 1992	FRX

Erythromycin derivatives

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

US Referenced Citations (1)

Foreign Referenced Citations (3)